Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivekimig in moderate to severe hidradenitis suppurativa
NCT07170917Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of brivekimig in hidradenitis suppurativa (HS), sponsored by Sanofi. Started Nov 2025; status: recruiting.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07170917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170917.